Intrapartum oral azithromycin for maternal infection prophylaxis and the risk of postpartum hemorrhage: A secondary analysis of the A‐ PLUS trial
International Journal of Gynecology & Obstetrics · 2026
DOI: 10.1002/ijgo.70777 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Larissa Sidze und 37 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham, Center for Research in Women's Health and Mary Heersink Institute for Global Health, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Postpartum Hemorrhage, Azithromycin, Anti-Bacterial Agents, Antibiotic Prophylaxis. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, Gates Foundation, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
Objective
A single oral dose of azithromycin (AZM) given during labor to women planning a vaginal delivery reduced maternal infections including sepsis, with a stronger effect in sub‐Saharan Africa than South Asia. Since maternal infection contributes to labor dysfunction and postpartum hemorrhage (PPH), we evaluated the effect of AZM on the risk of PPH and blood transfusion.
Methods
This was an unplanned secondary analysis of the Azithromycin Prevention in Labor Use Study (A‐PLUS) randomized controlled trial at eight sites in seven low‐ and middle‐income countries in sub‐Saharan Africa, South Asia, and Latin America. The population consisted of pregnant women in labor at ≥28 weeks' gestation in health facilities randomized to either 2 g AZM or placebo. Based on an intent‐to‐treat analysis, the risk of PPH and blood transfusion was compared between AZM and placebo arms using Poisson regression adjusting for arm and site as fixed effects. The main outcome measures were (1) PPH (500 mL or greater) after delivery; and (2) postpartum blood transfusion after delivery.
Results
A total of 29 278 participants were randomized to APLUS; 14 590 to AZM and 14 688 to placebo. The risk of PPH did not significantly differ between AZM and placebo arms (1.4% in AZM; 1.6% in placebo; relative risk [RR] = 0.88; 95% confidence interval [CI]: 0.73, 1.07). The risk of blood transfusion also did not significantly differ between AZM and placebo arms (0.5% in AZM; 0.5% in placebo; RR = 0.90; 95% CI: 0.65, 1.25). There was also evidence indicating that the effect of AZM on the risk of blood transfusion, but not PPH, was beneficial in sub‐Saharan Africa but not in South Asia ( P value for two‐way interaction = 0.002).
Conclusion
A single intrapartum oral dose of AZM did not significantly reduce the overall risk of PPH or blood transfusion. ClinicalTrials.gov Identifier: NCT03871491.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Alabama at Birmingham, Center for Research in Women's Health and Mary Heersink Institute for Global Health, Birmingham, Alabama, USA.
- RTI International, Research Triangle Park, North Carolina, USA.
- University Teaching Hospital, Lusaka, Zambia.
- Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India.
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
Förderung
- NICHD NIH HHS
- Gates Foundation
- Foundation for the National Institutes of Health
- School of Medicine, Boston University
- RTI International
- North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill
- Heersink School of Medicine, University of Alabama at Birmingham
- University of Colorado
Zitieren
APA
Sidze, L., Moore, J. L., Carlo, W. A., Mwenechanya, M., Chomba, E., Hemingway-Foday, J. J., Kavi, A., Metgud, M. C., Goudar, S. S., Derman, R., Lokangaka, A. L., Tshefu, A. K., Bauserman, M. S., Bose, C. L., Shivkumar, P., Waikar, M., Patel, A. B., Hibberd, P. L., Nyongesa, P., …, & A‐PLUS Trial Group (2026). Intrapartum oral azithromycin for maternal infection prophylaxis and the risk of postpartum hemorrhage: A secondary analysis of the A‐ PLUS trial. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70777
Vancouver
Sidze L, Moore JL, Carlo WA, Mwenechanya M, Chomba E, Hemingway-Foday JJ, et al. Intrapartum oral azithromycin for maternal infection prophylaxis and the risk of postpartum hemorrhage: A secondary analysis of the A‐ PLUS trial. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.70777
BibTeX
@article{Sidze2026,
author = {Sidze, Larissa and Moore, Janet L and Carlo, Waldemar A and Mwenechanya, Musaku and Chomba, Elwyn and Hemingway-Foday, Jennifer J and Kavi, Avinash and Metgud, Mrityunjay C and Goudar, Shivaprasad S and Derman, Richard and Lokangaka, Adrien L and Tshefu, Antoinette K and Bauserman, Melissa S and Bose, Carl L and Shivkumar, Poonam and Waikar, Manjushri and Patel, Archana B and Hibberd, Patricia L and Nyongesa, Paul and Esamai, Fabian and Ekhaguere, Osayame A and Bucher, Sherri L and Jessani, Saleem and Tikmani, Shiyam Sunder and Saleem, Sarah and Goldenberg, Robert L and Billah, Sk Masum and Lennox, Ruth and Haque, Rashidul and Petri, William A and Figueroa, Lester and Mazariegos, Manolo and Krebs, Nancy F and Nolen, Tracy L and Koso-Thomas, Marion and McClure, Elizabeth M and Tita, Alan T N and A‐PLUS Trial Group, A‐PLUS Trial Group},
title = {Intrapartum oral azithromycin for maternal infection prophylaxis and the risk of postpartum hemorrhage: A secondary analysis of the A‐ PLUS trial},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
doi = {10.1002/ijgo.70777}
}
EUVIMED